Chemotherapy for advanced prostate cancer: Results of new clinical trials and future studies

被引：11

作者：

Armstrong A.J. ^{[1
]}

Carducci M.A. ^{[1
]}

机构：

[1] Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231

来源：

Current Oncology Reports | 2005年 / 7卷 / 3期

关键词：

Prostate Cancer; Docetaxel; Mitoxantrone; Advanced Prostate Cancer; Ixabepilone;

D O I：

10.1007/s11912-005-0077-y

中图分类号：

学科分类号：

摘要：

Our understanding of the role of chemotherapy for advanced prostate cancer has improved considerably in 2004 with the publication of two large randomized phase III trials and the approval by the US Food and Drug Administration of docetaxel and prednisone for metastatic hormone-refractory disease. Although treatment is still considered palliative in nature, studies of chemotherapy for metastatic hormone-refractory prostate cancer (HRPC) have demonstrated improved overall survival compared with older regimens as well as clinically significant improvements in important endpoints, such as quality of life and time to progression. In particular, docetaxel has emerged as first-line therapy on an every-3-week schedule for metastatic HRPC, replacing mitoxantrone, as recently reported in the TAX327 trial. Docetaxel and estramustine combinations have the disadvantage of significant cardiovascular and gastrointestinal toxicity, and further use of estramustine is likely unwarranted as first-line therapy. Future trials examining novel biologic agents and combination therapies should use single-agent docetaxel as the reference standard. The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation. Copyright © 2005 by Current Science Inc.

引用

页码：220 / 227

页数：7

共 56 条

[1]

Tannock I.F., de Wit R., Berry W.R., Et al., Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N. Engl. J. Med., 351, pp. 1502-1512, (2004)

[2]

Petrylak D.P., Tangen C.M., Hussain M.H.A., Et al., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N. Engl. J. Med., 351, pp. 1513-1520, (2004)

[3]

Kantoff P.W., Halabi S., Conaway M., Et al., Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study, J. Clin. Oncol., 17, pp. 2506-2513, (1999)

[4]

Bubley G.J., Carducci M.A., Dahut W., Et al., Eligibility and response guidelines for phase III clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen working group, J. Clin. Oncol., 17, pp. 3461-3467, (1999)

[5]

Pound C.R., Partin A.W., Eisenberger M.A., Et al., Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, pp. 1591-1597, (1999)

[6]

Eisenberger M.A., Partin A.W., Pound C., Et al., Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: Update, Proc. ASCO, 22, (2003)

[7]

Small E.J., Halabi S., Dawson N.A., Et al., Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583), J. Clin. Oncol., 22, pp. 1025-1033, (2004)

[8]

Scher H.I., Eisenberger M., D'Amico A.V., Et al., Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate specific antigen: Recommendations from the Prostate-Specific Antigen working group, J. Clin. Oncol., 22, pp. 537-556, (2004)

[9]

Matzkin H., Eber P., Todd B., Et al., Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer, Cancer, 70, pp. 2302-2309, (1992)

[10]

Scher H.I., Kelly W.K., Zhang Z.F., Et al., Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer, J. Natl. Cancer Inst., 91, pp. 244-251, (1999)

← 1 2 3 4 5 6 →